We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A governmental commission in the UK has called for the establishment of an open-access database of information for certain high-risk Phase I clinical trials, along with 21 other recommendations that are intended to prevent any repeat of the catastrophic Phase I clinical trial of the gene therapy TGN1412.
The Secretary’s Advisory Committee on Human Research Protections (SACHRP) is in need of new leadership, as Ernest Prentice is stepping down as chairman.
A new subcommittee within the HHS Secretary’s Advisory Committee on Human Research Protections will develop recommendations on research protections for people with impaired decisionmaking capability starting early next year.
A new subcommittee within the HHS Secretary’s Advisory Committee on Human Research Protections will develop recommendations on research protections for people with impaired decisionmaking capability starting early next year.
Merck announced Aug. 17 that it will soon start allowing HIV/AIDS patients who are out of other options to take an experimental new drug it is developing.
GlaxoSmithKline (GSK) has revised the prescribing information for its attention-deficit/hyperactivity disorder (ADHD) drug Dexedrine to indicate that the drug can cause sudden death in patients with heart abnormalities.
Novartis’ cancer drug Gleevec and other drugs in its class can put patients at risk of heart failure, according to a study published in the July 23 issue of Nature Medicine.
GlaxoSmithKline has announced an agreement with the U.S. government to provide a stockpile of its anti-viral drug in preparation for a potential influenza pandemic.
Eli Lilly’s antidepressant Prozac does not lower risk of relapse or help anorexia nervosa patients who have restored their body weight maintain it, according to a study published in the June 14 issue of the Journal of the American Medical Association.